Search results - 2 results
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
Therapy COVID-19 Female Global Burden of Disease Hospitalization Humans Immunization, Passive Male mortality Respiration, Artificial SAFETY SARS-CoV-2 Standard of Care Treatment Outcome Abstract: ...
Population vulnerability to COVID-19 in Europe: a burden of disease analysis
Disability (YLD) from the Global Burden of Disease (GBD) study help to characterise the extent of these effects. Our aim was to identify the countries across Europe that have populations at highest risk from ...